The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer

Eur Urol. 2015 Jan;67(1):30-32. doi: 10.1016/j.eururo.2014.07.030. Epub 2014 Aug 6.

Authors

Anna Orsola¹, Joaquim Bellmunt²

Affiliations

¹ Bladder Cancer Center at DFCI, Boston, MA, USA.
² Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA; University Hospital Del Mar-IMIM, Barcelona, Spain. Electronic address: [email protected].

PMID: 25108578
DOI: 10.1016/j.eururo.2014.07.030

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Neoplasms / drug therapy*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*